实用肝脏病杂志 ›› 2010, Vol. 13 ›› Issue (4): 263-264.doi: 10.3969/j.issn.1672-5069.2010.04.008

• 论著 • 上一篇    下一篇

T淋巴细胞亚群水平对阿德福韦酯治疗慢性乙型肝炎疗效的影响*

蒋阳昆,涂燕云,许剑,陈黎,林海   

  1. 530011 南宁市 广西中医学院附属瑞康医院肝胆内科(蒋阳昆,涂燕云,陈黎,林海);
    贵阳中医学院第二附属医院消化内科(许剑)
  • 收稿日期:2009-12-06 出版日期:2010-08-10 发布日期:2016-04-18
  • 作者简介:蒋阳昆 男,38岁,主治医师。主要从事肝胆疾病的诊断与治疗学研究.E-mail:gx2005jyk@163.com
  • 基金资助:
    广西中医学院自然科学基金资助项目(编号:2005040)

T-lymphocyte subsets levels on the efficacy of adefovir in the treatment of patients with chronic hepatitis B

JIANG Yangkun,TU Yanyun,XU Jian,et al.   

  1. Ruikang Hospital,Affiliated to Guangxi TCM University,Nanning 530011,Guangxi,China
  • Received:2009-12-06 Online:2010-08-10 Published:2016-04-18

摘要: 目的 观察T淋巴细胞亚群变化对阿德福韦酯治疗CHB患者疗效的影响。方法 根据治疗前T淋巴细胞亚群水平将42例CHB患者分为CD4+/CD8+细胞比值低水平组和高水平组,观察阿德福韦酯治疗12个月的疗效。结果 治疗后两组患者ALT和AST水平下降,但高水平组下降更明显(P<0.05);治疗后两组患者血清HBV DNA水平分别为4.2±1.2copies/ml和4.5±1.5 copies/ml(P>0.05);治疗后高水平组患者HBeAg阴转率为38.89%(7/18),低水平组为18.75%(3/16,P<0.05)。结论 治疗前T淋巴细胞亚群水平较高的CHB患者在应用阿德福韦酯治疗后疗效较好。

关键词: 慢性乙型肝炎, T淋巴细胞亚群, 阿德福韦酯, 疗效

Abstract: Objective To observe the efficacy of adefovir on patient with CHB. Method 42 CHB patients were divided into two groups based on the ratio of CD4+/CD8+. Two groups received adefovir for 12 months. Results After 12 months treatment,the high level group got a better improvement in the liver function,HBV DNA loss and HbeAg negative rate. Conclusion Pre-treatment levels of T lymphocyte subgroup in CHB will influence the efficacy of adefovir dipivoxil treatment.

Key words: Chronic hepatitis B, T lymphocyte subset, Adefovir, Afficacy